dm+d

Unassigned

New Medicines

Primary progressive multiple sclerosis (MS)

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Highly selective and reversible (noncovalent) Bruton tyrosine kinase inhibitor, taken twice daily
MS estimated prevalence is 190 cases per 100,000 population. MS is more than twice as common in females than males. The highest prevalence for MS occurs in the 60 to 69 years age group for both sexes. The MS estimated incidence in England is between 8 and 11 new cases per 100,000 population [1].
Primary progressive multiple sclerosis (MS)
Oral

Relapsing multiple sclerosis (MS)

Information

New molecular entity
Roche
Roche

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Highly selective and reversible (noncovalent) Bruton tyrosine kinase inhibitor, taken twice daily
MS estimated prevalence is 190 cases per 100,000 population. MS is more than twice as common in females than males. The highest prevalence for MS occurs in the 60 to 69 years age group for both sexes. The MS estimated incidence in England is between 8 and 11 new cases per 100,000 population [1].
Relapsing multiple sclerosis (MS)
Oral